Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Bristol-Myers Squibb Co., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of long-term activity ratios from March 2022 through March 2026 reveals divergent trends in asset utilization and equity efficiency, characterized by a steady decline in fixed asset productivity and a significant shift in equity turnover.

Net Fixed Asset Turnover
A consistent downward trend is observed over the analyzed period. The ratio declined from a peak of 7.90 in June 2022 to 6.33 by March 2026. This persistent decrease indicates that the company is generating progressively less revenue for every unit of net fixed assets, which may suggest an increase in capital expenditures that has not yet translated into proportional revenue growth.
Total Asset Turnover
Total asset efficiency remained relatively stagnant between 0.46 and 0.49 for the first two years of the period. However, a gradual improvement emerged starting in the second half of 2023, with the ratio ascending to 0.56 by March 2026. This suggests that while fixed asset efficiency declined, the overall utilization of the total asset base improved, indicating better management of current assets or other non-fixed investments.
Equity Turnover
The equity turnover ratio exhibited a stark structural break in the first quarter of 2024. Between March 2022 and December 2023, the ratio fluctuated within a narrow range of 1.41 to 1.55. In March 2024, the ratio spiked to 2.76 and remained at elevated levels through March 2026, ending at 2.42. This abrupt increase suggests a significant reduction in the equity base relative to sales, typically indicative of substantial share buybacks or a shift in the capital structure.

In summary, the data reflects a period of transition. The contraction in net fixed asset turnover suggests diminishing returns on physical infrastructure investments. Conversely, the rise in total asset turnover and the sharp escalation in equity turnover indicate an optimization of the broader asset base and a fundamental change in how shareholder equity is utilized to generate revenue.


Net Fixed Asset Turnover

Bristol-Myers Squibb Co., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Revenues
Property, plant and equipment
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Net fixed asset turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Property, plant and equipment
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the investment activity ratios reveals a persistent decline in the efficiency of fixed asset utilization over the period from March 2022 to March 2026.

Net Fixed Asset Turnover Trend
A consistent downward trajectory is observed in the net fixed asset turnover ratio, which decreased from 7.77 in March 2022 to 6.33 by March 2026. This trend indicates that the company is generating progressively less revenue per unit of investment in net fixed assets.
Revenue Dynamics
Revenues exhibited moderate volatility, fluctuating between a low of 10.97 billion USD in September 2023 and a peak of 12.50 billion USD in December 2025. Despite these periodic upticks, the overall revenue growth remained relatively flat compared to the growth of the asset base.
Fixed Asset Expansion
Property, plant, and equipment showed a steady and nearly uninterrupted increase, rising from 6.05 billion USD in March 2022 to 7.66 billion USD by March 2026. This continuous growth in the asset base suggests significant ongoing capital expenditure.
Asset Productivity Insight
The decline in the turnover ratio is primarily driven by the fact that capital investment in property, plant, and equipment has outpaced revenue growth. The most pronounced erosion of efficiency occurred throughout 2023, where the ratio fell from 7.30 in March to 6.77 in December, reflecting a period where asset expansion did not yield a corresponding increase in sales volume.

Total Asset Turnover

Bristol-Myers Squibb Co., total asset turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Revenues
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Total asset turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the investment activity ratios reveals a steady improvement in the efficiency of asset utilization over the period from March 31, 2022, to March 31, 2026. The total asset turnover ratio increased from 0.46 to 0.56, indicating that the organization is generating more revenue per unit of assets held.

Revenue Performance
Revenues exhibited relative stability with moderate fluctuations, generally ranging between $10.9 billion and $12.5 billion. While there was a period of stagnation between 2022 and 2023, a gradual upward trend emerged in 2024 and 2025, peaking at $12.5 billion in December 2025 before a slight correction in the first quarter of 2026.
Asset Base Dynamics
A consistent contraction in the total asset base is observed. Total assets declined from a high of $103.0 billion in March 2022 to $86.5 billion by March 2026. This reduction was most pronounced in the final quarter of 2025 and the first quarter of 2026, where assets dropped from $90.0 billion to $86.5 billion.
Total Asset Turnover Efficiency
The improvement in the total asset turnover ratio is primarily driven by the reduction in the asset base rather than significant revenue growth. The ratio remained relatively flat between 0.46 and 0.49 from March 2022 through December 2023. However, a distinct positive trend began in 2024, with the ratio climbing to 0.52 by December 2024 and reaching its peak of 0.56 by March 2026. This suggests a strategic optimization of the balance sheet, resulting in a leaner asset structure relative to the revenue generated.

Equity Turnover

Bristol-Myers Squibb Co., equity turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Revenues
Total BMS shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Equity turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Total BMS shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial trajectory from March 2022 to March 2026 is characterized by stable revenue streams contrasted with a significant restructuring of the equity base, which has fundamentally altered the equity turnover ratio.

Revenue Trends
Quarterly revenues remained relatively consistent, fluctuating within a narrow range between 10.966 billion and 12.502 billion US dollars. A modest growth trend is observable through 2024 and 2025, though the overall volatility remains low, suggesting a steady top-line performance.
Equity Base Analysis
A sharp contraction in total shareholders' equity occurred between December 31, 2023, and March 31, 2024, where the value fell from 29.430 billion to 16.490 billion US dollars. Following this abrupt decline, equity levels exhibited a gradual recovery trend, rising to 20.068 billion US dollars by March 31, 2026.
Equity Turnover Dynamics
The equity turnover ratio experienced a dramatic shift inversely correlated with the change in shareholders' equity. From March 2022 to December 2023, the ratio remained stable, oscillating between 1.41 and 1.55. Starting in March 2024, the ratio spiked to 2.76 and peaked at 2.96 in December 2024. The subsequent increase in the equity base led to a moderate decline in the turnover ratio, which settled at 2.42 by March 2026.

The observed escalation in the equity turnover ratio is primarily attributable to the substantial decrease in the equity denominator rather than exponential revenue growth. This pattern suggests a shift toward a more leveraged capital structure or a significant return of capital to shareholders, thereby increasing the revenue generated per dollar of equity.